Rare disease

Pancreatic neuroendocrine tumour

7 clinical trials
5 recruiting
12 countries

Quick filters

Clinical trials for Pancreatic neuroendocrine tumour

7 trials across Europe

See all trials →

Quick filters

7 Clinical trials

Pancreatic neuroendocrine tumour

Recruiting

Registered drugNo placebo

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Registered drugNo placebo

Austria

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Exelixis Inc.

Contact Research Centre

Endometrial cancer+12

Recruiting

InvestigationalNo placebo

A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

InvestigationalNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Belzutifan
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Neuroendocrine tumour+6

Recruiting

Registered drugNo placebo

Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Dotatate
Sponsor:Region Hovedstaden

Contact Research Centre

Neuroendocrine tumour+6

Recruiting

Registered drugNo placebo

Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

Registered drugNo placebo

Denmark

Participants:18–64 years · 65+ years
Substances:Pyruvic Acid
Sponsor:Region Hovedstaden

Contact Research Centre

Neuroendocrine tumour+2

Recruiting

Registered drugNo placebo

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Registered drugNo placebo

Belgium

Participants:18–64 years · 65+ years
Substances:Everolimus
Sponsor:Antwerp University Hospital

Contact Research Centre

Pancreatic neuroendocrine tumour

Not yet recruiting

Registered drugNo placebo

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine
Sponsor:Institut Gustave Roussy

Contact Research Centre

See all trials →

Pancreatic neuroendocrine tumour

Clinical trials for Pancreatic neuroendocrine tumour

Pancreatic neuroendocrine tumour

A study comparing XL092 versus everolimus in patients with previously treated advanced or metastatic neuroendocrine tumors

Endometrial cancer+12

A study of belzutifan and lenvatinib for patients with von Hippel-Lindau disease-associated tumors or other specific solid tumors.

Neuroendocrine tumour+6

Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

Neuroendocrine tumour+6

Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

Neuroendocrine tumour+2

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Pancreatic neuroendocrine tumour

Randomized phase III adjuvant capecitabine plus temozolomide versus surveillance in patients with resected stage I‑III pancreatic neuroendocrine tumors

Filter the trials

Prefer not to search? Our Concierge searches the trials for you.